(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2011 (17.03.2011)

PCT

(10) International Publication Number
WO 2011/030106 A1

(51) International Patent Classification:
A61K 31/352 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2010/001710

(22) International Filing Date:
10 September 2010 (10.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0915877.5 10 September 2009 (10.09.2009) GB

(71) Applicant *(for all designated States except US)*: **E-THERAPEUTICS PLC** [GB/GB]; Block B, Holland Park, Holland Drive, Newcastle Upon Tyne, Tyne & Wear NE2 4LZ (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YOUNG, Malcolm, Philip** [GB/GB]; e-Therapeutics Plc, Block B, Holland Park, Holland Drive, Newcastle Upon Tyne, Tyne & Wear NE2 4LZ (GB). **MCKEOWN, Philip** [GB/GB]; e-Therapeutics Plc, Block B, Holland Park, Holland Drive, Newcastle Upon Tyne, Tyne & Wear NE2 4LZ (GB).

(74) Agent: **GILHOLM, Stephen, Philip**; IPheions Intellectual Property, The Hawk Creative Business Park, Easingwold, York YO61 3FE (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/030106 A1

(54) Title: CANCER CELL APOPTOSIS

(57) Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin- dependent kinases, *e.g.* CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.